Neuren Pharmaceuticals Limited Appendix 4D Half-year report 1. Company details Name of entity: Neuren Pharmaceuticals Limited ARBN: 111 496 130 Reporting period: For the half-year ended 30 June 2026 Previous period: For the half-year ended 30 June 2025 2. Results for announcement...
Neuren Pharmaceuticals: Half Yearly Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Neuren Pharmaceuticals
- European Commission grants marketing authorisation for DAYBU
- Neuren H1 2026 Financial Results Webinar on 26 August 2026
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
- DAYBU recommended for approval in the European Union
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
Later from Neuren Pharmaceuticals
- Growing royalty anchors Neuren first ever dividend program
- Investor presentation, 26 August 2026
- Dividend/Distribution - NEU
- Corporate Presentation, 2 September 2026
- Update - Dividend/Distribution - NEU
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals